JP2004502739A5 - - Google Patents

Download PDF

Info

Publication number
JP2004502739A5
JP2004502739A5 JP2002508462A JP2002508462A JP2004502739A5 JP 2004502739 A5 JP2004502739 A5 JP 2004502739A5 JP 2002508462 A JP2002508462 A JP 2002508462A JP 2002508462 A JP2002508462 A JP 2002508462A JP 2004502739 A5 JP2004502739 A5 JP 2004502739A5
Authority
JP
Japan
Prior art keywords
gly
asp
peptide
ala
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002508462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502739A (ja
JP3618736B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/021944 external-priority patent/WO2002004008A2/en
Publication of JP2004502739A publication Critical patent/JP2004502739A/ja
Publication of JP2004502739A5 publication Critical patent/JP2004502739A5/ja
Application granted granted Critical
Publication of JP3618736B2 publication Critical patent/JP3618736B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002508462A 2000-07-12 2001-07-12 トロンビン由来ペプチドを使用した治療法 Expired - Fee Related JP3618736B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21758300P 2000-07-12 2000-07-12
PCT/US2001/021944 WO2002004008A2 (en) 2000-07-12 2001-07-12 Methods of therapy with thrombin derived peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004232356A Division JP2005036007A (ja) 2000-07-12 2004-08-09 トロンビン由来ペプチドを使用した治療法

Publications (3)

Publication Number Publication Date
JP2004502739A JP2004502739A (ja) 2004-01-29
JP2004502739A5 true JP2004502739A5 (enExample) 2005-01-06
JP3618736B2 JP3618736B2 (ja) 2005-02-09

Family

ID=22811661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002508462A Expired - Fee Related JP3618736B2 (ja) 2000-07-12 2001-07-12 トロンビン由来ペプチドを使用した治療法
JP2004232356A Withdrawn JP2005036007A (ja) 2000-07-12 2004-08-09 トロンビン由来ペプチドを使用した治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004232356A Withdrawn JP2005036007A (ja) 2000-07-12 2004-08-09 トロンビン由来ペプチドを使用した治療法

Country Status (10)

Country Link
US (5) US6867190B2 (enExample)
EP (1) EP1253937B1 (enExample)
JP (2) JP3618736B2 (enExample)
CN (1) CN100500211C (enExample)
AT (1) ATE249238T1 (enExample)
AU (2) AU7890701A (enExample)
CA (1) CA2415778A1 (enExample)
DE (2) DE60100740T4 (enExample)
TW (1) TWI257307B (enExample)
WO (1) WO2002004008A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU2002241917B2 (en) * 2000-07-12 2006-06-15 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
EP1467749B1 (en) * 2002-01-16 2011-04-06 Capstone Therapeutics Corp. Thrombin derived peptides for promoting cardiac tissue repair
EP1539214A4 (en) * 2002-07-02 2008-01-02 Orthologic Corp Thrombin
CA2491135A1 (en) * 2002-07-02 2004-01-15 The Board Of Regents, The University Of Texas System Thrombin peptide derivative dimers
CA2484383C (en) * 2002-07-12 2016-05-31 Cook Incorporated Medical device coated with a bioactive agent
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ATE553203T1 (de) 2003-02-12 2012-04-15 Monsanto Technology Llc Baumwolle ereignis mon 88913 und verbindungen und methoden zur detektion davon
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
DK1559431T3 (da) 2003-12-31 2007-07-30 Orthologic Corp Farmaceutisk sammensætning til thrombinpeptidderivater
JP2008510726A (ja) * 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
JP2006321740A (ja) * 2005-05-18 2006-11-30 Kanazawa Univ 虚血後血管新生促進剤
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
CA2663547C (en) * 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
WO2008124173A1 (en) * 2007-04-10 2008-10-16 The Board Of Regents, The University Of Texas System Combination therapy for cardiac revascularization and cardiac repair
US8202528B2 (en) * 2007-06-05 2012-06-19 Abbott Cardiovascular Systems Inc. Implantable medical devices with elastomeric block copolymer coatings
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
US8586398B2 (en) * 2008-01-18 2013-11-19 Miasole Sodium-incorporation in solar cell substrates and contacts
WO2009120304A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
CA2722620A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
US8952129B2 (en) * 2008-03-26 2015-02-10 The Board Of Regents Of The University Of Texas System Method of treating degenerative diseases
JP2011515471A (ja) * 2008-03-26 2011-05-19 オーソロジック コーポレイション 急性心筋梗塞を処置するための方法
US20110319340A1 (en) * 2008-09-19 2011-12-29 The Board Of Regents, The University Of Texas System Methods for treating cancer
US20130101574A1 (en) * 2010-06-11 2013-04-25 Darrell H. Carney Methods of using thrombin peptide derivatives
GB201314312D0 (en) * 2013-08-09 2013-09-25 Regentec Ltd Composition and delivery system
US20160039876A1 (en) 2014-03-28 2016-02-11 Claresa Levetan Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
WO2020210087A1 (en) * 2019-04-12 2020-10-15 Affirmed Pharma, Llc Rusalatide acetate compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5244460A (en) * 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
US6086866A (en) 1993-04-29 2000-07-11 Kouri; Roger Khalil Use of platelet-derived growth factor to improve collateral circulation
EP0867450B1 (en) * 1995-10-24 2004-08-11 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute TFPI-related Peptides which inhibit growth of smooth muscle cells
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6033436A (en) * 1998-02-17 2000-03-07 Md3, Inc. Expandable stent
AU760664B2 (en) 1998-04-17 2003-05-22 Angiogenix, Inc. Therapeutic angiogenic factors and methods for their use
ES2229788T3 (es) 1998-10-26 2005-04-16 Ludwig Institute For Cancer Research Uso del gen o proteina vegf-c o vegf-d para prevenir la restenosis.
US6363938B2 (en) * 1998-12-22 2002-04-02 Angiotrax, Inc. Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair

Similar Documents

Publication Publication Date Title
RU2400256C2 (ru) Захват эндотелиальных клеток-предшественников элюирующим лекарственные средства имплантируемым медицинским устройством
ES2379574T3 (es) Copolímeros de metacrilato para dispositivos médicos
US7887572B2 (en) Implantable devices for accelerated healing
US20070003589A1 (en) Coatings for implantable medical devices containing attractants for endothelial cells
US8062350B2 (en) RGD peptide attached to bioabsorbable stents
US20090299133A1 (en) Ventricular infarct assist device and methods for using it
DE60100740D1 (de) Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten
JP5752033B2 (ja) 遺伝子組み換えゼラチンを含む血管新生誘導剤
JP5153340B2 (ja) 薬剤放出制御組成物および薬剤放出性医療器具
US20070293937A1 (en) Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating
JP2008521495A (ja) 生体有益性コーティングとしてのポリ（エステルアミド）誘導体
WO1998020027B1 (en) Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
JP2003521354A (ja) 医療装置
JP2002528420A5 (enExample)
WO2010147109A1 (ja) 遺伝子組み換えゼラチン及び塩基性線維芽細胞増殖因子を含む血管新生誘導剤
JP4338516B2 (ja) 血管新生剤
ZA200603110B (en) Caspase inhibitors as coating material for medical products for inhibiting restenosis
JP2008529742A (ja) 内皮細胞の誘引物質を含む植込み型医療装具の被膜
DE60239705D1 (de) Thrombin-derivierten peptiden zur förderung von herzgewebsreparatur
US20250281679A1 (en) Biomimetic coating for endovascular stent
TH78436A (th) การใช้เพปไทด์ซึ่งได้มาจากธรอมบินในการผลิตยาเพื่อรักษาความผิดปกติที่เกี่ยวข้องกับหลอดเลือดหัวใจ
JP2024542778A5 (enExample)
JP2024542779A5 (enExample)